Comparable Transaction Analysis

*A comparable transaction analysis (or “precedent transactions”) values a company by looking at the prices paid in recent M&A deals for similar businesses. A competitor was acquired last year at 12x EBITDA; therefore, your target company is worth 12x EBITDA. The method is straightforward and credit-

ible to boards and buyers—but be aware that transaction multiples are often higher than trading multiples, reflecting acquisition premiums and synergy expectations.*

How it works

Step 1: Identify relevant M&A deals. Look for acquisitions of competitors or similar companies over the past 3–5 years.

Step 2: Extract transaction multiples. Calculate what multiple was paid: acquisition price divided by the target’s EBITDA, revenue, earnings, or other metric at the time of the deal.

Step 3: Adjust for timing and differences. Account for differences in size, growth, profitability, and time elapsed since the deal.

Step 4: Apply to your target. Use the median transaction multiple to value your target company’s earnings or EBITDA.

Example. SoftCo acquired SmallComp (a competitor) in 2023 for 500 million. SmallComp had EBITDA of 40 million. The transaction multiple was 12.5x EBITDA. Your target has similar profiles (competitor, similar growth, similar margins). Its EBITDA is 50 million. Implied value: 50 million × 12.5x = 625 million.

Key difference: transaction multiples vs. trading multiples

A critical insight: companies typically sell for higher multiples than they trade at publicly.

Trading multiples. What public companies trade at in the stock market. A software company might trade at 25x EBITDA.

Transaction multiples. What acquirers pay for companies. That same software company, acquired, might go for 30–35x EBITDA.

The difference (5–10x EBITDA, or 20–40% premium) reflects:

1. Control premium. Buyers pay extra to own 100% of a company. Public markets price minority stakes.

2. Synergies. The buyer can cut costs, cross-sell, leverage better technology or distribution. They are willing to pay for those gains.

3. Strategic value. A buyer might value a company more than a financial investor would, if it fits a strategic need.

4. Urgency. In a competitive auction, multiple bidders drive prices up.

Advantages of comps transactions

Market-tested. Real money changed hands. The valuation is not theoretical.

Synergy reality. If you are the acquirer, you can indeed capture synergies, so paying transaction prices might be justified.

Defensible. Boards often prefer transaction comps because they reflect what the market has paid, not what a model predicts.

M&A context. In acquisition scenarios, transaction comps are the primary valuation tool.

Disadvantages

Limited sample. Fewer transactions than public companies, so you might have only 3–4 comparables. Small sample size introduces noise.

Stale data. If the most recent comparable deal was three years ago, the valuation might be outdated (markets have moved, the target has grown or declined).

Synergy bias. A buyer pays 12x because they can achieve 2x EBITDA of synergies, worth 3x EBITDA. If you are a financial buyer without those synergies, you shouldn’t pay 12x.

Public vs. private. Acquisitions are often of private companies, whose growth rates and risk profiles might differ from public comparables.

Adjustments for transaction comps

Size adjustment. If the biggest comparable deal was 300 million and your target is 800 million, apply a size discount (larger deals might trade at lower multiples).

Growth rate. A 30% growth target should trade higher than a 10% growth comparable. Adjust by 1–2x per percentage point of growth difference.

Profitability. If your target has better margins, adjust upward.

Time passed. If a deal closed three years ago and was 12x EBITDA, but market multiples have compressed since, adjust downward.

Synergies vs. standalone. If you are a financial buyer, subtract estimated synergy value from the transaction multiple. If you are a strategic buyer, keep the synergy premium.

Adjusting for synergies

Transaction prices embed synergy expectations. If a buyer paid 15x EBITDA for a target whose standalone value is 12x EBITDA, the 3x EBITDA premium (20% of transaction value) represents synergies.

If you are the acquirer and can achieve the same synergies, the 15x price is justified. If you cannot achieve them, you should bid less.

To estimate standalone value, subtract synergies from transaction price:

Standalone value = Transaction price minus estimated synergies

If a deal was 500 million and involved 50 million of cost synergies (valued at 5x EBITDA), the standalone value was roughly 500 - (50 × 5) = 250 million.

What happens after the transaction

In competitive auctions, prices paid are often elevated (multiple bidders drive up the price). In bilateral or negotiated deals, prices are often lower. This is selection bias—if you cherry-pick only competitive deals, you are biasing multiples upward.

Look for a mix of deal types to get a balanced perspective.

Integration with DCF

Comparable transaction analysis is most useful as a sanity check on DCF. If your DCF implies a 20x EBITDA valuation and transaction comps show 12x, something is off. Either your DCF assumptions are too aggressive, or you are buying into a specific strategic scenario not reflected in typical M&A pricing.

See also